Stay updated on Efgartigimod in Post-COVID-19 POTS Clinical Trial

Sign up to get notified when there's something new on the Efgartigimod in Post-COVID-19 POTS Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Efgartigimod in Post-COVID-19 POTS Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    Added a Locations section listing California, Illinois, Maryland, Massachusetts, Ohio, Tennessee, Texas, and Utah, and updated the page version to v3.3.3. Removed the prior location sections for those states and the HHS Vulnerability Disclosure, corresponding to the v3.3.2 changes.
    Difference
    0.9%
    Check dated 2025-12-23T22:00:43.000Z thumbnail image
  4. Check
    23 days ago
    No Change Detected
  5. Check
    44 days ago
    Change Detected
    Summary
    The Publications section text was updated to clarify PubMed as the source for publications. The page revision number was updated from v3.2.0 to v3.3.2.
    Difference
    0.1%
    Check dated 2025-11-25T10:43:06.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    The page shows the removal of a government funding/operating status notice. The core study information, including title, status, enrollment, eligibility, and locations, remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-11-18T06:55:12.000Z thumbnail image
  7. Check
    66 days ago
    Change Detected
    Difference
    0.4%
    Check dated 2025-11-03T20:59:54.000Z thumbnail image
  8. Check
    95 days ago
    Change Detected
    Summary
    Major update: adds a government funding/operating status notice and updates version to v3.2.0, replacing the previous v3.1.0.
    Difference
    3%
    Check dated 2025-10-06T05:36:10.000Z thumbnail image
  9. Check
    102 days ago
    Change Detected
    Summary
    Added a new version label (v3.1.0) and removed several drug-safety related sections (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) indicating a shift in content scope.
    Difference
    0.3%
    Check dated 2025-09-29T03:06:41.000Z thumbnail image

Stay in the know with updates to Efgartigimod in Post-COVID-19 POTS Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Efgartigimod in Post-COVID-19 POTS Clinical Trial page.